These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15577138)

  • 1. [SERM and quality of bone].
    Sohen S
    Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contribution of bone quality to fracture risk].
    Mori S
    Clin Calcium; 2004 Oct; 14(10):33-8. PubMed ID: 15577129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
    Vignot E; Meunier PJ
    Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Who are the candidates for the treatment by raloxifen ?].
    Hagino H
    Clin Calcium; 2004 Oct; 14(10):111-3. PubMed ID: 15577141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Raloxifene hydrochloride].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract]   [Full Text] [Related]  

  • 11. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of raloxifene as a SERM on bone metabolism].
    Ohta H
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():411-8. PubMed ID: 16689343
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
    Sakai A; Nakamura T
    Clin Calcium; 2010 Mar; 20(3):322-9. PubMed ID: 20190361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

  • 17. Raloxifene.
    Gass ML
    South Med J; 1999 Nov; 92(11):1120-3. PubMed ID: 10586846
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
    Riggs BL; Melton LJ
    J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.